Objective:To prepare EGF-coupling bovine serum albumin nano-carrier as a new way for initiative targeted drug delivery of epidermal growth factor receptor(EGFR) with broad range of expression in tumor cell. Methods:albumin nano-carrier was prepared by second phacoemulsification and solvent evaporation technology,and epidermal growth factor(EGF) was conjugated with albumin nano-carrier by chemical crosslinking reagents for EGF coupling bovine serum albumin nano-carrier. Results:The prepared nano-carrier then underwent isotope labeling,then the coupling effect of EGF and its coupling level were certified by sephadex column and polyacrylamide gel electrophoresis(SDS-PAGE). Conclusion:Success in the preparation of the smaller bovine serum albumin nano-carrier and EGF coupling bovine serium albumin nano-carrier establish the experimental foundation for further exploration of its targeting of tumor cells in vitro and distribution in vivo.

AIM: In order to prolong release time and increase bioavailability of puerarin,the sustained release solid dispersion was prepared.METHODS: Sustained-release capsules were prepared by solid dispersing technology.And the dissolution in vitro of pueriarin and excipients that affect the dissolution were studied. RESULTS: Dissolution of pueriarin solid dispersion was affected by kinds of ethyl cellulose(EC);With the increase of the EC-puerarin ratio,the releasing speed of pueriarin becoming slowly.And the release rate conformed to apparent zero-order kinetics.The releasing effect could be adjusted by adding releasing-regulator HPMC. CONCLUSION: The prepared puerarin capsule has a marked sustained-release effect.

Objective In order to observe the dispersing form, the sustained release solid dispersion was prepared. Methods Sustained-release solid dispersion was prepared by taking ethyl cellulose as carrier. And the X-ray diffraction, differential scanning calotimetery (DSC) were used to evaluate the dispersing form of puerarin in the preparation and to study the solubility in vitro. Results The X-ray diffraction experiment showed that the puerarin was existed in molecuar and minicrystal form. DSC Experiment showed that there is no puerarin crystal in the solid dispersion. The test for stripping showed that thare was a better releasing results in the sustained-release capsula. Conclusion The sustained-release solid dispersion can disperse the puerarin highly to increase its bioavailability. The prepared capsula has a marked sustained-release effect.

Although it has been widely used clinically,Chaihu Guizhi decoction was seldom reported being used to treat infantile diseases.In the recent years.more and more children have been caught by Recurrent Respiratory Tract Infections(RRTI),Chaihu Guizhi decoction should be paid attention for its good effects in treating RRTI.This article summarized related reports on this subject.hoping to provide evidence for reasonable application of Chaihu Guizhi decoction in treating pediatrics diseases.

OBJECTIVE To study the effect of stapes footplate fixation of on the middle ear transfer function. METHODS A finite element model of stapes footplate fixation was developed by changing the Young's module after constructing a normal adult finite element ear model, which was developed based on a normal temporal bone scanning data using Micro-CT. The displacement at the umbo of tympanic membrane and at the center of the stapes footplate were calculated under certain sound pressure. RESULTS In case of stapes footplate fixation, compared with the normal data, the displacement at the center of stapes footplate was reduced significantly (-47 dB), but which was mild at the umbo of tympanic membrane. CONCLUSION The stapes footplate fixation ear model in this study showed an obvious displacement reduction of the stapes footplate. Further study using fresh temporal bone is necessary.

Purpose: The aim of the present study was to investigate the expression of breast cancer resistance protein (BCRP) in primary breast carcinoma and to determine whether such expression can predict survival. Methods: Expression of BCRP in 60 breast cancer patients was determined by immunohistochemistry on formalin-fixed, paraffin-embedded tumor section. The relationship between the expression of BCRP with the clinicphathological characteristics and the prognosis of breast cancer patients were also analyzed. Results: ①BCRP expression was observed in 21 of 60 (35%) cases.② BCRP expression was more frequently observed in patients with lymph node metastasis or hormone receptor (P 0. 05) .③Kaplan-Meier analyses revealed that BCRP expression associated only with disease-free survival (DFS) (P 0. 05) . ④In univariate and multivariate Cox regression analyses, tumor size, lymph node metastasis and estrogen receptor (ER) was associated with DFS and OS (P